kashmirlife.net ·
Kashmir Scientist Led Company Raises Rs 20 Cr to Advance Affordable Cancer and Gene Therapies in India
Topic context
This topic has been covered 289242 times in the last 7 days across our monitored publishers.
The full article is on the original publisher site.
AI insight
AI-generatedCellogen Therapeutics, a biotech startup, raised $2M to develop affordable cell and gene therapies in India. The company aims to slash CAR-T therapy costs by ~90%, targeting price-sensitive Indian market. Impact is company-specific and early-stage; no immediate sector-wide price or supply effect. Commercial mechanism is weak (early-stage R&D funding, no revenue or margin impact yet).
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Cellogen Therapeutics raised Rs 20 crore (~$2 million) from Kotak Alternate Asset Managers.
- Funding aims to advance CAR-T clinical programs and therapies for blood disorders and cancers.
- Cellogen targets reducing CAR-T treatment cost from $500k-700k to about one-tenth.
- Phase I human clinical trials planned with Christian Medical College Vellore, pending regulatory approvals.
- Previous Rs 15 crore stake acquisition by Natco Pharma.
Related stories
tribune.com.pk
Pakistan Played Very Sincere Role in US Iran Mediation Efforts Pm Shehbaz in Beijing
theguardian.com
Michigan Climate Crisis
emirates247.com
Global Stocks Rally as Oil and Dollar Ease on Middle East Peace Hopes
graphic.com.gh
Ghana News Savannah Regional Tour President Mahama Cuts Sod for Projects Inspects Regional Hospital Opens Ict Centre
dailynews.co.tz